
Demonstrated Safety Profile in Wet AMD
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.1
VIEW 1 and VIEW 2: Most common adverse reactions (≥1%)1

Less common serious adverse reactions reported in
<1% of the patients treated with EYLEA
were hypersensitivity, retinal tear, and endophthalmitis.1
VIEW 1 Extension: Most common adverse reactions2


No new safety signals compared with the known profile of EYLEA in Wet AMD.2
AE, adverse event.

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.
